Mental health care company, COMPASS Pathways (CMPS) has priced its upsized IPO in the U.S. of 7.5M (6.7M) American Depositary Shares (ADSs) representing 7.5M ordinary shares at $17.00/ADS, higher than previous range of $14-$16, for total gross proceeds of $127.5M.
Trading kicks off September 18.
Underwriters’ over-allotment is an additional 1.125M ADSs.
Closing date is September 22.
COMPASS is currently evaluating COMP360 in conjunction with psychological support in a Phase 2b trial and plans to report data from this trial in late 2021.
Depression has biological, social, psychological, environmental, genetic, and stress-related determinants, and therefore treatment options are wide-ranging and often combined. The following table includes representative ranges and approximate costs for existing treatments of depression as well as their methods of delivery.
Previously: COMPASS Pathways sets IPO terms (Sept. 14)